Health-care companies rose as investors bet on anti-obesity products. Omada Health shares jumped after the maker of digital products that help track diet and other diabetes factors made its ...

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

Mr. Funk was the managing editor of Pleroma Media, and worked as a breaking news reporter at The Messenger after spending 25 ...

Shares in pharmaceuticals group Novo Nordisk (NVO) remained in good shape today despite reports that its weight loss drugs ...

The European Medicines Agency's (EMA) safety committee (PRAC) has concluded its review of medicines containing semaglutide ...

The European Medicines Agency has identified a rare eye condition risk linked to Novo Nordisk’s semaglutide drugs.

Human insulin presents Indian companies an opportunity estimated at Rs 450 crore per annum in India and $157 million/annum in ...

The European Medicines Agency’s safety committee found that an eye condition called NAION is a “very rare” side effect of semaglutide, a key ingredient in diabetes and obesity drugs. It could affect ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Novo Nordisk's (NVO) weight loss drug semaglutide (Ozempic, Wegovy, Rybelsus) is linked to a rare eye condition called NAION ...

The EMA’s drug safety committee launched a review of medicines containing semaglutide — the active ingredient in Ozempic, Wegovy and Rybelsus — in January.

AS TikTok’s popularity shows no signs of waning, the app has quickly become a hub for promoting and sharing health content – including supposed quick fixes for shedding weight, crammed into ...